A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 276
- Registration Number
- NCT04288778
- Locations
- ๐ฎ๐ณ
Chellaram Diabetes Institute, Pune, India
๐ฎ๐ณLifecare Hospital and Research Centre, Bengaluru, India
๐ฎ๐ณThumbay Hospital New life / Endocrinology, Hyderabad, India
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 150
- Registration Number
- NCT03768960
- Locations
- ๐ฎ๐ณ
Basavatarakam Indo-American Hospital, Hyderabad, India
๐ฎ๐ณPost Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India
๐ฎ๐ณSparsh Hospitals & Critical Care (Pvt) Ltd, Bhubaneshwar, India
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 100
- Registration Number
- NCT03733925
- Locations
- ๐ฎ๐ณ
ChanRe Rheumatology & Immunology Center & Research, Bangalore, India
๐ฎ๐ณApollo Hospitals, Bhubaneswar, India
๐ฎ๐ณIndraprastha Apollo Hospital, New Delhi, India
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 178
- Registration Number
- NCT03604224
- Locations
- ๐ฎ๐ณ
Dr. A. Ramachandran's Diabetes Hospitals, Chennai, India
๐ฎ๐ณApollo Hospitals, Kolkata, India
๐ฎ๐ณDiacon Hospital, Bangalore, India
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-Cell
- Interventions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 40
- Registration Number
- NCT03476655
- Locations
- ๐ฎ๐ณ
Apollo Hospitals International Limited, Ahmedabad, India
๐ฎ๐ณHealthcare Global (HCG) Hospital, Bangalore, India
๐ฎ๐ณFortis Memorial Research Institute, Gurgaon, India
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-Cell
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Johnson & Johnson Private Limited
- Target Recruit Count
- 75
- Registration Number
- NCT03190330
- Locations
- ๐ฎ๐ณ
Avron Hospitals Pvt. Ltd, Ahmedabad, India
๐ฎ๐ณPost Graduate Institute of Medical Education And Research PGIMER, Chandigarh, India
๐ฎ๐ณBasavatarakam Indo-American Hospital, Hyderabad, India
A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Johnson & Johnson Private Limited
- Registration Number
- NCT02608359